Clinical Trial Update: Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating vildagliptin as add-on therapy to metformin for type 2 diabetes, reporting on efficacy and long-term safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 2, Phase 3 | Status: COMPLETED